SLC2A4 and Insulin resistance: In conclusion, our results demonstrate that 2′,3,3,5′-Tetramethyl-4′-nitro-2′H-1,3′-bipyrazole could be a very useful hypoglycemic agent for the treatment of T2D due to its multifactorial effects, including (i) the reduction in insulin resistance, (ii) increase in glucose uptake by the skeletal muscle, (iii) improvement in the lipid profile, (iv) reduction in oxidative stress and inflammation, and (v) the activation of the GLUT4-AMPK pathway.